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In The Lancet, Patricia Hewitt and colleagues1 report 
the prevalence of hepatitis E virus (HEV) RNA in 
225 000 blood donations from southeast England. 
Their study was based on HEV RNA detection by means 
of reverse transcriptase real-time PCR in minipools 
of 24 donations or fewer collected in a 1-year period 
(2012–13). They deﬁ ned the rate of transmission from 
HEV-containing blood components, investigated the 
factors associated with transmission, and looked at 
the outcomes of recipients of HEV-containing blood 
components. HEV RNA was noted in roughly one in 
every 2848 (0·04%) blood donations tested. When 
projected across England, this prevalence suggests 
that about 80 000–100 000 acute HEV infections are 
likely to have occurred countrywide during the year of 
the study. 
Overall, 79 HEV genotype 3 RNA-positive donations, 
56 of which (71%) were seronegative, were used to 
prepare 129 blood components; 62 were transfused, 
resulting in 18 documented infections (42%) 
among the 43 recipients who could be followed 
up. The components associated with transmission 
included platelet preparations, red cells, granulocyte 
pools, and fresh frozen plasma. The median times 
for seroconversion and duration of infection 
depended on the degree of immunosuppression. 
Ribavirin treatment was started in one severely 
immunosuppressed infected recipient, and the 
level of immunosuppression was reduced in one 
moderately immunosuppressed patient and one 
severely immunosuppressed patient, to induce viral 
clearance. Among the other patients, four died, one 
remained viraemic, and the remaining infections 
cleared spontaneously. These results are interesting 
and can inform the ongoing debate about HEV and 
blood safety.
The HEV genome was cloned in 1990 and this virus 
was identiﬁ ed as the main causative agent of enterally 
transmitted non-A, non-B hepatitis. Four genotypes, 
1 to 4, have subsequently been identiﬁ ed in human 
beings. HEV was initially thought to be present mainly 
in low-income or middle-income areas, where poor 
hygiene conditions favour faecal–oral transmission 
of genotypes 1 and 2, resulting in frequent sporadic 
cases and large outbreaks of acute hepatitis related to 
the contamination of drinking water. More recently, 
HEV genotypes 3 and 4 were reported as zoonotic 
infections in the developed world, causing acute 
hepatitis cases in occupationally exposed individuals 
or consumers of infected meat that had been 
insuﬃ  ciently cooked.2 
Acute hepatitis E is generally mild and self-limiting. 
However, HEV infection is not always harmless. Severe 
cases, including subfulminant or fulminant hepatitis, 
have been reported in patients with underlying chronic 
liver disease.3 HEV infection can induce various types 
of eventually severe extrahepatic manifestations, such 
as neurological symptoms, kidney injury, pancreatitis, 
or thrombocytopenia, and aplastic anaemia;2 a higher 
mortality owing to HEV infection has been reported 
in pregnant women than in the general population 
during large outbreaks in low-income areas, the causes 
of which remain debated.2 Chronic HEV infection has 
been reported in immunocompromised patients, 
including recipients of solid organ transplants and 
haemopoietic stem cell transplants, patients receiving 
chemotherapy, HIV-infected individuals, and patients 
taking steroids.4–6 Chronic HEV infection can cause 
chronic liver disease that rapidly evolves towards 
cirrhosis in roughly 10% of cases, with a risk of lethal 
liver failure.7 
Blood transfusion is known to be a route of HEV 
transmission in immunocompromised patients.8,9 We 
recently reported in The Lancet that 5 of 367 consecutive 
liver transplant recipients (1·4%) acquired chronic 
hepatitis E through blood transfusion and subsequently 
developed persistent liver graft damage.10 The 
prevalence of HEV RNA in blood donations in England 
reported by Hewitt and colleagues is in keeping with 
ﬁ ndings from studies in other European countries 
(one in 1240 donations in Germany11 and one in 
1761 donations in the Netherlands12). Despite this high 
prevalence, the high rate of transmission by infected 
blood or blood products, the non-negligible morbidity 
and mortality related to HEV infection (especially in 
patient populations exposed to blood or blood product 
transfusion), and the lack of eﬃ  cient antiviral therapy, 
Hewitt and colleagues surprisingly conclude that “there 
seems no pressing need to move rapidly with the 
introduction of donation screening”. 
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Although cost-eﬀ ectiveness studies have not been 
done and might not show a substantial economic 
beneﬁ t of blood donation screening for HEV, the 
history of viral infections in blood transfusion should 
help stakeholders to make quick decisions. The public 
scandals related to the delay in implementation of 
HIV antibody screening in blood donations in several 
countries in the 1980s taught us that societies in 
high-income countries are extremely sensitive to the 
safety of medical procedures, especially those related to 
the use of blood and blood products. 
The medical threat of hepatitis E is obviously 
not comparable to that of HIV. However, it is 
useful to remember the conditions that led to the 
implementation of nucleic acid testing of blood 
donations for other transfusion-transmitted viral 
infections 15 years ago. Because the transmission of 
HIV and hepatitis C virus (HCV) had been substantially 
reduced by the use of serological testing for p24 antigen 
and speciﬁ c antibodies, the implementation of nucleic 
acid testing in blood banks was not estimated to be cost 
eﬀ ective and was not recommended by most scientiﬁ c 
experts. Despite this view and because of the context, 
the decision was made by the political authorities and 
blood services to implement pooled nucleic acid testing 
in Europe and the USA. In the USA, in the ﬁ rst year only 
62 HCV RNA-positive, antibody-negative donations 
were identiﬁ ed among more than 16·3 million 
donations screened (1:263 000), whereas only 4 HIV 
RNA-positive, p24 antigen-negative donations were 
found among more than 12·6 million donations 
screened (1:3 150 000).13 Numbers of the same order 
of magnitude have been reported in western Europe.14 
Despite this modest impact, nucleic acid testing of 
blood donations is still obligatory or recommended for 
HIV, HCV, and hepatitis B virus.
The risk of transmission for HEV at present is far 
higher than for viruses such as HIV, and should be 
interpreted in the context of the poor sensitivity 
and speciﬁ city of anti-HEV antibody testing for 
infectivity in the blood bank setting. The potential 
clinical results of blood-borne HEV infection should 
not be downplayed; in particular, the risk of serious 
complications and death exists. Thus, on the basis 
of Hewitt and colleagues’ and other studies, I believe 
that systematic screening of blood components 
for markers of hepatitis E infection should be 
implemented in areas where HEV is endemic (eg, the 
European Union), based on HEV RNA detection. No 
doubt this position will be debated and, whatever the 
experts think, a political decision will have to be made. 
I suspect that pooled HEV RNA testing will become 
obligatory in blood banks soon.
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